Hard to Treat Diseases Inc. (HARD TO TREAT DISEASES INC) aktie

Hard to Treat Diseases Inc. manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningococcal Group A, C bivalent polysaccharide conjugate, recombinant hepatitis B, poliomyelitis, and pneumococcal polysaccharide conjugate vaccines. It also provides biopharmaceuticals, including recombinant human coagulation factor VIII for injection, insulin aspart injection, cerebroprotein hydrolysate for injection, recombinant human basic fibroblast growth factor, insulin glargine injection, mouse nerve growth factor for injection, trastuzumab injection, bevacizumab injection, adalimumab injection, recombinant human epidermal growth factor eye drop, recombinant human interferon a2b injection, reteplase (rPA ), and levonorgestrel silastic implant products. In addition, the company offers plasma products comprises human coagulation factor IV, human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, and human immunoglobulin (pH4) for intravenous injection; and chemicals that consists of olaparib tablets, enzalutamide soft capsules, and eribulin mesilate injection. The company markets its products through distribution and sales network. Hard to Treat Diseases Inc. is based in Clearwater, Florida.